Development and utilization of a drug information system in the Japanese pharmaceutical industry

被引:1
|
作者
Yamamoto, M
Onaka, Y
Sakakibara, K
Negi, H
Funabashi, S
Hirata, T
Kawasaki, T
Saito, H
Kawai, T
Okada, S
机构
[1] Daiichi Pharmaceut Co Ltd, PMS Adm Dept, Chuo Ku, Tokyo, Japan
[2] Daiichi Pharmaceut Co Ltd, Dept Informat Syst, Chuo Ku, Tokyo, Japan
来源
MEDICAL INFORMATICS | 1998年 / 23卷 / 01期
关键词
drug information; Q & A; pharmaceutical industry; medical representatives;
D O I
10.3109/14639239809001389
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Pharmaceutical companies are responsible for providing updated, relevant information on the efficacy, safety and quality of drugs to medical professionals and finally to patients. To fulfill this responsibility, we must always endeavour to collect and evaluate the relevant information. We developed a drug information database system called Advanced Medical Online Network of Daiichi (AMOND) to manage various information generated during development of new products and after launch of the products using the classification format for retrieval. This system has been used for 9 years for the purpose of supporting medical representatives who play a primary role in the drug information services in the pharmaceutical industry. This system is incorporated into an on-line network system, and can be directly accessed by more than 1200 people at 11 branch offices and more than 110 subbranches all over the country. We upgraded this system to AMOND-II to improve the function, including retrieval and output abilities. As a result, utilization by users of this system increased six times. We report on the improved system, AMOND-II and our experience of the system.
引用
收藏
页码:31 / 41
页数:11
相关论文
共 50 条
  • [41] DRUG DISCOVERY IN THE PHARMACEUTICAL-INDUSTRY - THE DEVELOPMENT OF ENDOTHELIN ANTAGONISTS
    DOHERTY, AM
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 1 - SOCED
  • [42] Stock price reaction to the drug development setbacks in the pharmaceutical industry
    Abramavicius, Silvijus
    Stundziene, Alina
    Korsakova, Laura
    Venslauskas, Mantas
    Stankevicius, Edgaras
    [J]. DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 29 (01) : 1 - 11
  • [43] REALISTIC GOALS FOR THE PHARMACEUTICAL-INDUSTRY IN ANTICANCER DRUG DEVELOPMENT
    JACKSON, RC
    [J]. BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 482 - 482
  • [44] Innovation in the pharmaceutical industry: The processes of drug discovery and development.
    Higginson, B
    [J]. R & D MANAGEMENT, 2004, 34 (01) : 104 - 104
  • [45] Role of population pharmacokinetics in drug development - A pharmaceutical industry perspective
    Samara, E
    Granneman, R
    [J]. CLINICAL PHARMACOKINETICS, 1997, 32 (04) : 294 - 312
  • [46] Future implications of ChatGPT in pharmaceutical industry: drug discovery and development
    Zhao, Ailin
    Wu, Yijun
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [47] Stock price reaction to the drug development setbacks in the pharmaceutical industry
    Silvijus Abramavičius
    Alina Stundžienė
    Laura Korsakova
    Mantas Venslauskas
    Edgaras Stankevičius
    [J]. DARU Journal of Pharmaceutical Sciences, 2021, 29 : 1 - 11
  • [48] Strategic Inertia and the Japanese Pharmaceutical Industry
    Slater, Stephanie
    Paliwoda, Stan
    Slater, Jim
    [J]. MULTINATIONAL BUSINESS REVIEW, 2008, 16 (04) : 1 - 23
  • [49] The Utilization of Quality KPIs in the Pharmaceutical Industry
    Torkko, Marianne
    Katajavuori, Nina
    Linna, Anu
    Juppo, Anne Mari
    [J]. JOURNAL OF PHARMACEUTICAL INNOVATION, 2014, 9 (03) : 175 - 182
  • [50] The Utilization of Quality KPIs in the Pharmaceutical Industry
    Marianne Torkko
    Nina Katajavuori
    Anu Linna
    Anne Mari Juppo
    [J]. Journal of Pharmaceutical Innovation, 2014, 9 : 175 - 182